FDA Grants Janssen Biotech’s Apalutamide Priority Review Designation to Treat Non-Metastatic CRPC January 2, 2018 The U.S. Food and Drug Administration (FDA) has granted priority review status to apalutamide — an investigational androgen receptor inhibitor — to treat men with non-metastatic castration-resistant prostate cancer (CRPC).Read more.Source: Prostate Cancer News Today Prostate Cancer News
The U.S. Food and Drug Administration (FDA) has granted priority review status to apalutamide — an investigational androgen receptor inhibitor — to treat men with non-metastatic castration-resistant prostate cancer (CRPC).Read more.Source: Prostate Cancer News Today
